ZGNX News and Press, Zogenix Inc. From 03/16/20

If you are young and you drink a great deal it will spoil your health, slow your mind, make you fat - in other words, turn you into an adult. "- P. J. O'Rourke Today, we take a developmental biotech company whose stock has been hit hard both by recent disappointing study results as well a...

On Feb. 27, shares of Zogenix (NASDAQ:ZGNX) , a California-based pharmaceutical company, slid by about 9%. This drop came on the heels of the company's announcement that the U.S. Food and Drug Administration (FDA) extended the review period for Fintepla, a product for which Zogenix submitted ...

GW Pharmaceuticals (NASDAQ: GWPH) boasts the first plant-based cannabinoid pharmaceutical agent on the market with its treatment, Epidiolex. The Food and Drug Administration approved Epidiolex in June 2018 as a treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrom...

Anaplan (NYSE: PLAN )  -29%   despite Q4 beat . More news on: Anaplan, Inc., Continental Resources, Inc., Nutanix, Inc., Stocks on the move, , Read more ...

EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for FINTE...

Zogenix ( ZGNX ) had announced results from its phase 3 study treating patients with Lennox-Gastaut Syndrome (LGS). The primary endpoint of the study was met , however, investors were disappointed in that they expected the reduction of monthly seizures to be greater than what was report...

Zogenix (NASDAQ: ZGNX) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We hosted a doc call last week with Dr. Kathryn Davis from UPenn Epilepsy Center to discuss Zogenix's recent Lennox Gastaut (LGS) Phase 3 data. While th...

EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2019, after the market clo...

Thesis Summary Zogenix, Inc. ( ZGNX ) is a pharmaceutical company that develops and commercializes therapies for rare diseases. Recently, some “disappointing” data on Fintepla sent the stock tumbling over 30%. However, I believe that the market has overreacted to the results,...

Zogenix offers Data for Fintepla, Markets React Negatively Zogenix (ZGNX) stock tumbled as the company reported mixed data from its Phase 3 clinical trial of Fintepla. The trial involved evaluating two doses of the lead drug candidate in patients suffering from a severe form of childhood o...